ACE2 News and Research

RSS

Placental cell-type productively infected with SARS-CoV-2

A new preprint describes the development of a new platform for evaluating the risk of SARS-CoV-2 infection in placental tissue.

2 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021

Curcumin, a bioactive component of turmeric, effectively neutralizes SARS-CoV-2 in vitro

The researchers investigated the neutralizing activity of turmeric root extract, curcumin-containing capsules, and pure curcumin against SARS-CoV-2.

1 Nov 2021

Study finds inhaled microspheres reduce SARS-CoV-2 infective effectiveness

A new study develops an inhaled microfluidic microsphere with a genetically engineered membrane from the ACE2 receptor-overexpressing cells and macrophages.

1 Nov 2021

The impact of SARS-CoV-2 variants on the COVID-19 epidemic in South Africa

A new study explores the role of new SARS-CoV-2 variants in sustaining the pandemic in South Africa.

31 Oct 2021

New Canadian serology solution for SARS-CoV-2 infections and vaccination

A new study developed a “Made-in-Canada” solution for enabling scalable and reproducible SARS-CoV-2 serology.

31 Oct 2021

The ability of natural flavonoids to inhibit SARS-CoV-2

A recent systematic review discusses naturally occurring flavonoids as a promising antiviral alternative against SARS-CoV-2.

31 Oct 2021

New evidence that SARS-CoV-2 virus can infect the inner ear

Many Covid-19 patients have reported symptoms affecting the ears, including hearing loss and tinnitus. Dizziness and balance problems can also occur, suggesting that the SARS-CoV-2 virus may be able to infect the inner ear.

29 Oct 2021

How long does natural or vaccine-induced immunity to COVID last?

Researchers present a comprehensive assessment on SARS-CoV-2 induced immunity.

28 Oct 2021

Structure of human-infecting canine coronavirus HuPn-2018 spike glycoprotein

As CCoV-HuPn-2018 has been recently isolated in a child's respiratory swab, researchers from the University Of Washington have been examining the structure of the virus.

28 Oct 2021

Chlorophyll catabolite pheophorbide A shows potential against SARS-CoV-2

A new study identifies a potent SARS-CoV-2 antiviral, Pheophorbide a (PheoA), which is a compound derived from the plant Marchantia polymorpha L.

27 Oct 2021

The difference in the dynamics of SARS-COV-2 variants

A new study provides a detailed description of the varying interactions between SARS-CoV-2 and the host cell ACE-2 receptor.

27 Oct 2021

Study shows efficacy of a heterologous vaccine regimen to induce mucosal protection against COVID-19

Researchers emphasize that an effective vaccine should induce mucosal immunity and prevent the nasal entry of SARS-CoV-2.

27 Oct 2021

Study of SARS-CoV-2 antibody seroprevalence among domestic cats

Researchers from the University of Veterinary Medicine Hannover have been investigating the spread of the disease in domestic cats in Europe.

27 Oct 2021

Model for the simulation of SARS-CoV-2 community transmission in congregate facilities

Researchers have examined the factors that caused the most significant outbreaks in congregate settings such as care homes and prisons.

27 Oct 2021

New study explains why Delta is so easily transmitted and infects people quickly

The Delta variant of SARS-CoV-2 has swept the globe, becoming the dominant variant within just a few months. A new study from Boston Children's Hospital, published today in Science, explains why Delta is so easily spread and infects people so quickly, and suggests a more targeted strategy for developing future COVID-19 vaccines and treatments.

27 Oct 2021

Cholesterol-lowering drugs not helpful in reducing COVID-related mortality or severity

In the worldwide effort to battle SARS-CoV-2, the virus that causes COVID-19, researchers have often turned to medications used as therapies for other conditions in the hopes of finding ones that either kill the coronavirus or lessen the impacts from its infection.

26 Oct 2021

A high-throughput pipeline for identifying nanobodies that target and neutralize SARS-CoV-2

Researchers in the United States have developed a cost-effective, high-throughput pipeline for identifying effective nanobodies that target and neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

26 Oct 2021

Study finds SARS-CoV-2 infection is proportional to cell surface ACE2 levels

Researchers from Oregon State University have developed a system to assess the ability of SARS-CoV-2 to bind to ACE2 orthologs.

26 Oct 2021

N501Y mutation in SARS-CoV-2 Delta variant is key to breakthrough infections

A study in the Philadelphia area found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants evolve to become more contagious and resistant to COVID-19 vaccines. In addition, depending on the sublineage, SARS-CoV-2 variants such as the Delta variant led to a three-fold increased risk for vaccine breakthrough cases.

25 Oct 2021